期刊文献+

小鼠雾化吸入羟喜树碱后原形药物经尿液粪便的排泄 被引量:1

Excretion of Unchanged Hydroxycamptothecine in Urine and Feces via Aerosol Inhalation in Mice
下载PDF
导出
摘要 目的研究小鼠雾化吸入羟喜树碱后原形药物经尿液、粪便的排泄。方法小鼠经雾化给药后,分别收集给药前及给药后0~3,~6,~9,~12,~24,~48 h的尿液和粪便样品,采用高效液相色谱法检测尿液和粪便中的原形药和代谢产物。结果原形药物主要从粪便中排出,粪便中原形药物在12 h内排泄速度很快,之后趋于平稳。尿液中前3 h羟喜树碱的排泄量最大,药物在肾脏不易蓄积。结论雾化吸入羟喜树碱后原形药物的代谢可能为其主要消除方式。 Objective To study the excretion of hydroxycamptothecine (HCPT) in urine and feces of mice via aerosol administration. Methods The urine and feces samples were collected at baseline and 0-3, 3-6, 6-9, 9-12, 12-24 and 24-48 h after aerosol administration. HPLC-FLD was used to determine the concentration of unchanged HCPT and its metabolites in the urine and feces. Results The unchanged drug was mainly excreted in the feces, with most of the drug excreted within the first 12 h. Excretion of HCPT in the urine largely occurred in the first 3 h without renal accumulation. Conclusion Hydroxycamptothecine is mainly excreted unchanged after aerosol administration in mice.
出处 《医药导报》 CAS 北大核心 2013年第3期297-300,共4页 Herald of Medicine
关键词 羟喜树碱 雾化 代谢 色谱法 高效液相 Hydroxycamptothecine Aerosol inhalation Metabolism High performance liquid chromatography
  • 相关文献

参考文献4

二级参考文献18

  • 1沈洁,韩宝惠,姜丽岩,赵怡卓,顾爱琴,周箴,冯光丽,施春雷,纪灏,熊丽纹,钟华,储天晴,张伟,李蓉.10-羟基喜树碱为主的非铂方案治疗复治非小细胞肺癌前瞻性临床研究[J].上海医学,2005,28(6):469-471. 被引量:4
  • 2廖美琳.非小细胞肺癌化疗、放疗联合治疗的进展[J].临床肿瘤学杂志,2006,11(3):161-168. 被引量:13
  • 3张湘茹,朱允中,修清玉,韩福才,刘端祺,储大同.伊立替康联合顺铂治疗晚期非小细胞肺癌临床报告[J].中华肿瘤杂志,2006,28(10):777-779. 被引量:13
  • 4[1]Schiller JH,Harrington D.Comparison of four chemotherapy rngimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98
  • 5[6]Perez Soler R,Fossella F V,Glisson B S,et al.Phase Ⅱ study of topotecan in patients with advarIced non-small-cell lung cancer previously untreated with chemotherapy[J].J Clin Onoul,1996,14(2):503-513
  • 6[7]Madan H.Jagasia,Corey J.langerweekly irinotecan and cisp latin in advanced non-small cell lung cancer.A muhicenter phase Ⅱ study[J].Clinical Cancer Research,2001,7(1):68-73
  • 7Giovanella BC, Stehlin JS, Hinz HR, et al. Preclinical evaluation of the anticancer activity and toxicity of 9 - nitro - 20 ( s ) - camptothecin ( Rubitecan). Int J Oncol,2002,20 ( 1 ) :81
  • 8Bernacki RJ, Pera P, Gambacorta P, et al. In vitro antitumor activity of 9 - nitrocamptothecin as a single agent and in combination with other antitumor drugs. Ann N Y Acad Sci,2000,922:293
  • 9Amorino GP, Hercules SK, Mohr PJ, et al. Preclinical evaluation of the orally active camptothecin analog, RFS - 2000 ( 9 - nitro - 20 ( s ) - camptothecin ) as a radiation enhancer. Int J Radiat Oncol Biol Phys , 2000,47 (20) :503
  • 10Hung CL, Doniger J, Palini A, et al. 9 - Nitrocamptothecin inhibits HIV - 1 replication in human periperal blood lymphocytes : a potential alternative for HIV - infection/AIDS therapy. J Med Virol, 2001,64 (3) :238

共引文献9

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部